Veteran leadership at the top. Accelerated development throughout.
[image placeholder – do not delete]
We are a global company committed to improving patient outcomes through the accelerated development and launch of important new treatment options for significant health conditions.
While the Sumitovant portfolio companies each focus on particular areas of human health, they share an unparalleled technology-enabled approach to drug discovery, development and commercialization that aims to accelerate and de-risk every aspect of the process from bench to bedside.
About Sumitovant Biopharma
Sumitovant Biopharma Ltd. (“Sumitovant”) is a global company that was launched on December 27, 2019 upon the completion of a strategic alliance between Sumitomo Dainippon Pharma (“DSP”) and Roivant Sciences Ltd. Sumitovant is a wholly-owned subsidiary of DSP and operates out of offices in New York and London. It is also the parent company of five biopharma companies: Myovant, Urovant, Enzyvant, Altavant and Spirovant.
Sumitovant is led by industry veteran, Myrtle Potter. As CEO, Potter has built a proven, leadership team that brings expertise and oversight to its family of five subsidiary biotech companies known as Vants. Sumitovant is the primary source of funding for each of the five Vants and also provides expert advice across a number of business and scientific disciplines to help the Vants accelerate the pace of medical innovation for patients who need new treatment options today. Sumitovant’s aim is to foster speed, agility, and efficiency as a core part of our biotech business model across the family of Vants as they advance their healthcare agendas around the global.
Sumitovant companies benefit from an unparalleled technology-enabled approach to drug discovery, development and commercialization that aims to accelerate and de-risk every aspect of the process from bench to bedside. This innovative model has fueled the company’s robust pipeline across its portfolio of companies with late stage clinical assets that are now moving to commercial stage. These treatments span a range of therapeutic areas with unmet medical needs including women’s and men’s health, urological diseases, rare diseases, and gene therapy.
Sumitovant’s potential competitive advantage is also powered by a robust technology platform comprising a computational ecosystem (DrugOME) and an embedded custom technology capability (Digital Innovation) that together help enable rapid and tailored data-driven decision-making across every aspect of the business.
Sumitovant’s proven leadership team, technology backbone and the support of industry powerhouse DSP, uniquely position Sumitovant and the Vants to accelerate the launch of important new treatment options and improve lives globally.
Myovant Sciences Ltd (“Myovant”) a public company that trades under the stock symbol MYOV, aspires to be the leading healthcare company focused on redefining care in men and women’s health. With three late-stage clinical programs ongoing for its lead clinical candidate, relugolix, in prostate cancer, uterine fibroids and endometriosis the company is transitioning to a commercial-stage company. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is the majority shareholder of Myovant. For more information, please visit the company’s website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Its lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Enzyvant Therapeutics is focused on transformative therapies for rare, often fatal, diseases. It is advancing two separate platforms based on two well-characterized technologies: T cell generation to treat profound immunodeficiency disorders, and recombinant human acid ceramidase (rhAC) to address the harmful impacts of excess ceramide build-up.
Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH).
Spirovant Sciences is focused on changing the course of cystic fibrosis and other pulmonary diseases. Its gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.